PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
14.4.2020 14:50:29 CEST | ViroGates | Company Announcement
Company Announcement No. 8-2020
14 April 2020
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that it has received the first order from Complejo Asistencial Universitario de León (León Hospital) in Spain. The hospital has implemented suPARnostic® TurbiLatex in clinical routine in the Emergency Department and is the first hospital in Spain to implement suPARnostic® in clinical routine. León Hospital is a 1056-bed university hospital in the Castilla y León region in Spain.
In addition to using suPAR as a routine marker for triaging of acute medical patients to avoid unnecessary admissions, suPARnostic® will also be used to triage patients admitted to the hospital with suspicion of a COVID-19 infection.
Jakob Knudsen, Chief Executive Officer of ViroGates, says: ”We are happy to announce the first clinical routine customer in Spain. This is a result of our dedication to the Spanish market, where we have established a solid footprint with sales representation since 2019.
We are looking forward to a long-term collaboration with León Hospital using suPARnostic® to support triaging of acute medical patients in the Emergency Department. We are, however, especially honoured to help during the COVID-19 outbreak for Léon Hospital to be able to better cope with the extraordinary workload associated with the high number of patients in need of care and the prioritizations needed to allocate resources optimally.”
The announcement can be found at https://www.virogates.com/investor/announcements
For further information please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.
ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Siemens ADVIA XPT instruments and Roche Diagnostics’ cobas instruments. ViroGates works with partners to develop solutions for other platforms.
Disclaimer
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
Contacts
- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com